



Attorney Docket No.: 6258.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lau et al

Serial No.: 09/996,023

Group Art Unit: 1626

Filed: November 16, 2001

Examiner: Stockton, Laura Lynne

Confirmation No: 2060

For: Glucagon Antagonists/Inverse Agonists

PATENT
RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

#10
3/26/03
RECEIVED

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents
Washington, DC 20231

Sir:

It is respectfully requested that the time for response to the Office Action dated October 11, 2002 be extended for a period of 2 months from January 11, 2003 to March 11, 2003. Applicant(s) hereby petition(s) for such extension of time.

Please charge the required fee, estimated to be \$410, with this application and to credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 11, 2003

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

03/20/2003 CV0111 00000132 141447 09996023

01 FC:1252 410.00 CH



23650

PATENT TRADEMARK OFFICE